[go: up one dir, main page]

AR062779A1 - Tratamiento de la esclerosis multiple (em) - Google Patents

Tratamiento de la esclerosis multiple (em)

Info

Publication number
AR062779A1
AR062779A1 ARP070104053A ARP070104053A AR062779A1 AR 062779 A1 AR062779 A1 AR 062779A1 AR P070104053 A ARP070104053 A AR P070104053A AR P070104053 A ARP070104053 A AR P070104053A AR 062779 A1 AR062779 A1 AR 062779A1
Authority
AR
Argentina
Prior art keywords
treatment
campath
multiple sclerosis
treatment cycle
cycle
Prior art date
Application number
ARP070104053A
Other languages
English (en)
Inventor
David Margolin
Andreas Sachse
Original Assignee
Genzyme Corp
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38734000&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR062779(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp, Bayer Schering Pharma Ag filed Critical Genzyme Corp
Publication of AR062779A1 publication Critical patent/AR062779A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Método para el tratamiento de la esclerosis multiple (EM) con Campath 1H con significativa eficacia y un favorable perfil de seguridad, que ofrece una aceptable relacion beneficio/riesgo. Se describe especialmente el uso de Campath 1H (alemtuzumab) para la produccion de un medicamento para el tratamiento de la esclerosis multiple (EM), que comprende un primer ciclo de tratamiento seguido de al menos otro ciclo de tratamiento con Campath 1H (alemtuzumab), donde cada ciclo de tratamiento comprende 1-5 dosis diarias que se aplican en días consecutivos, donde la dosis diaria es >0 y <= 12 mg, y donde cada ciclo de tratamiento está separado del ciclo siguiente por al menos 1-24 meses. También se describen regímenes de tratamiento que comprenden la administracion de menos de 12 mg/día de Campath 1H durante un período de 1-5 días consecutivos.
ARP070104053A 2006-09-13 2007-09-13 Tratamiento de la esclerosis multiple (em) AR062779A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84425106P 2006-09-13 2006-09-13
EP06090169 2006-09-14

Publications (1)

Publication Number Publication Date
AR062779A1 true AR062779A1 (es) 2008-12-03

Family

ID=38734000

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070104053A AR062779A1 (es) 2006-09-13 2007-09-13 Tratamiento de la esclerosis multiple (em)

Country Status (21)

Country Link
EP (4) EP2066352B1 (es)
JP (6) JP5872756B2 (es)
KR (2) KR20150039879A (es)
CN (1) CN102652832A (es)
AR (1) AR062779A1 (es)
BR (1) BRPI0716929A8 (es)
CA (1) CA2662531A1 (es)
CY (1) CY2016019I1 (es)
DK (1) DK2066352T3 (es)
ES (2) ES2917882T3 (es)
HR (1) HRP20160211T1 (es)
HU (2) HUE026740T2 (es)
IL (3) IL197236A (es)
LT (1) LTC2066352I2 (es)
LU (1) LU93092I2 (es)
MX (2) MX354080B (es)
PL (2) PL3028718T3 (es)
PT (2) PT2066352E (es)
RS (1) RS54658B1 (es)
SI (1) SI2066352T1 (es)
WO (1) WO2008031626A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9498528B2 (en) 2006-09-13 2016-11-22 Genzyme Corporation Treatment of multiple sclerosis (MS)
HUE026740T2 (en) 2006-09-13 2016-07-28 Alcafleu Man Gmbh & Co Kg Treatment of Multiple Sclerosis (MS) with Campath-1H
MY160126A (en) 2009-05-13 2017-02-28 Genzyme Corp Anti-human cd52 immunoglobulins
AR095199A1 (es) 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
TW201841653A (zh) * 2017-04-21 2018-12-01 美商建新公司 以抗-cd52抗體治療多發性硬化症
US20220015500A1 (en) * 2018-12-12 2022-01-20 University Of Delaware Vibrational device and methods for mitigating symptoms of freezing of gait

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5846534A (en) 1988-02-12 1998-12-08 British Technology Group Limited Antibodies to the antigen campath-1
GB9125768D0 (en) 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
HUE026740T2 (en) 2006-09-13 2016-07-28 Alcafleu Man Gmbh & Co Kg Treatment of Multiple Sclerosis (MS) with Campath-1H

Also Published As

Publication number Publication date
ES2917882T3 (es) 2022-07-12
JP2016175929A (ja) 2016-10-06
EP2444104A3 (en) 2012-10-24
SI2066352T1 (sl) 2016-05-31
CN102652832A (zh) 2012-09-05
LTPA2016019I1 (lt) 2016-06-27
DK2066352T3 (en) 2016-02-29
AU2007296857A1 (en) 2008-03-20
JP2019167385A (ja) 2019-10-03
HRP20160211T1 (hr) 2016-03-25
LU93092I2 (de) 2016-08-01
IL197236A0 (en) 2011-08-01
IL240394B (en) 2018-02-28
KR101583587B1 (ko) 2016-01-08
BRPI0716929A8 (pt) 2019-02-05
IL240394A0 (en) 2015-09-24
CA2662531A1 (en) 2008-03-20
PL2066352T3 (pl) 2016-05-31
EP2444104A2 (en) 2012-04-25
EP3028718A1 (en) 2016-06-08
JP2010503631A (ja) 2010-02-04
KR20090063215A (ko) 2009-06-17
LTC2066352I2 (lt) 2017-09-25
PT3028718T (pt) 2022-06-09
JP6257287B2 (ja) 2018-01-10
EP2066352A1 (en) 2009-06-10
BRPI0716929A2 (pt) 2013-09-17
IL257341A (en) 2018-03-29
JP2014058555A (ja) 2014-04-03
RU2009113665A (ru) 2010-10-20
WO2008031626A1 (en) 2008-03-20
PT2066352E (pt) 2016-03-31
MX354080B (es) 2018-02-12
EP2066352B1 (en) 2015-12-02
ES2563068T3 (es) 2016-03-10
EP2433649A3 (en) 2012-10-31
KR20150039879A (ko) 2015-04-13
HUS1600028I1 (hu) 2016-07-28
RS54658B1 (sr) 2016-08-31
EP2433649A2 (en) 2012-03-28
JP5872756B2 (ja) 2016-03-01
PL3028718T3 (pl) 2022-11-21
HK1136773A1 (en) 2010-07-09
JP2018024655A (ja) 2018-02-15
EP3028718B1 (en) 2022-03-23
HUE026740T2 (en) 2016-07-28
CY2016019I2 (el) 2016-10-05
JP2021107423A (ja) 2021-07-29
CY2016019I1 (el) 2016-10-05
MX2009002660A (es) 2009-06-11
IL197236A (en) 2015-08-31

Similar Documents

Publication Publication Date Title
MX2019002265A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
ECSP20069416A (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak
EP4272818A3 (en) Thrombolytic agent for the treatment of thromboembolism
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
EA200970237A1 (ru) Применение тенектеплазы для лечения острого ишемического инсульта
BRPI0415953B8 (pt) formulação de dosagem de liberação controlada e conjunto de formas de dosagem de liberação controlada
AR119158A1 (es) Tratamientos de angioedema hereditario
AR062779A1 (es) Tratamiento de la esclerosis multiple (em)
MX2020010697A (es) Kit, composicion y terapia de combinacion para el sindrome del cromosoma x fragil.
PH12019500328A1 (en) Aza-indazole compounds for use in tendon and/or ligament injuries
CL2020002544A1 (es) Inhibidor de ret para uso en tratar cáncer que tiene una alteración de ret
AR119159A1 (es) Tratamientos de angioedema
CO2019004004A2 (es) Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
AR115913A1 (es) Formas de dosificación oral biodisponibles, uso, métodos
BR112021018994A2 (pt) Formulação de combinação tripla de baixa dose
PA8549401A1 (es) Complejo que comprende factor inhibidor de osteoclastogenesis y polisacarido
MX2021009219A (es) Triamtereno o nolatrexed para su uso en el tratamiento de la fenilcetonuria.
CO5700723A2 (es) Uso de un derivado de amina ciclica especifico o de sus sales farmaceuticamente aceptables para tratar y prevenir la insuficiencia cardiaca
MX2023014898A (es) Terapia combinada anti-vhc ventajosa.
NO20054034L (no) Fremgangsmate for behandling av hypotyroidisme.
BRPI0507985A (pt) derivados de piperazina uréia para o tratamento de endometriose
AR126393A1 (es) Terapia combinada para el tratamiento de enfermedades hepáticas
BR0311209A (pt) Método de produção de unidades de dosagem farmacêuticas para administração oral, uso de etonogestrel, e, tablete
AR118933A1 (es) Dosificación del inhibidor de kras para el tratamiento de cánceres

Legal Events

Date Code Title Description
FC Refusal